간장 ( 肝臟 ) 및 담도 ( 膽道 ) : 간세포암에 대한 화학색전요법의 항종양 효과

Eighty-seven TACEs were performed in 38 patients with hepatocellular carcinoma: one in 16 patients; twice in seven patients; three times in seven patients; four times in four patients; and five times in four patients. In all patients, TACE was performed with adriamycin, mitomycin-C and lipiodol. In 21 patients, embolization with gelfoam powders were added following TACE. Six patients had the hepatocellular carcinoma of 4.0~4.9 cm in diameter: 14 patients, 5.0~9.9 cm; and 18 patients, larger than 10 cm. Response rate was evaluated in 33 patients, among whom fifteen patients (45$) achieved response (complete response, 6%; partial response, 33%). The cumulative survival rates at one year and two years for 38 patients were 55.3$ and 23.2%, respectively, with the median survival time of 12.0 months. Sex, ascites, HBsAg, esophageal varix, liver cirrhosis, gelfoam embolization, serum albumin level, size of the tumor, and a-fetoprotein were analyzed to investigate the effect of TACE on survival time, demonstrating that no significant differences in the survival times were observed between these factors except HBsAg. Theses results suggest that TACE is not curable for hepatocellular carcinoma, however prolong the life span in patients with hepatocellular carcinoma.